Timo Minssen

Timo Minssen

Professor

ORCID: 0000-0002-3286-4888
31 - 40 out of 63Page size: 10
Sort by: Title

  1. Mixed views on Broad’s fate after EPO revokes CRISPR patent

    Timo Minssen

    18/01/2018

    1 Media contribution

    Press/Media: Press / Media

  2. Medicinalindustri vil fortsat skjule oplysninger om forsøg

    Timo Minssen

    01/02/2018

    1 Media contribution

    Press/Media: Press / Media

  3. Los secretos comerciales, un obstáculo para la producción de una vacuna contra la Covid-19

    Timo Minssen

    14/08/2020

    1 Media contribution

    Press/Media: Press / Media

  4. Locus licenses CRISPR tech to Janssen in potential $818m deal

    Timo Minssen

    09/01/2019

    1 Media contribution

    Press/Media: Press / Media

  5. LSPN Europe 2017: Broad had ‘no clue’ about CRISPR licensing in agriculture

    Timo Minssen

    07/12/2017

    1 Media contribution

    Press/Media: Press / Media

  6. Key takeaways from IAM’s 2020 Pharma and Biotech IP event

    Timo Minssen

    06/02/2020

    1 Media contribution

    Press/Media: Press / Media

  7. Juridisk krig for milliarder

    Timo Minssen

    14/02/2011

    1 Media contribution

    Press/Media: Press / Media

  8. Interview with Danish Radio (DR) on compulsory licensing issues

    Timo Minssen

    12/02/2021

    1 Media contribution

    Press/Media: Press / Media

  9. Interview on the Role of Patents and Licensing in the Governance of Human Genome Editing

    Timo Minssen

    01/06/2021

    1 Media contribution

    Press/Media: Press / Media

  10. Interview for WHO: Regulating digital health

    Timo Minssen

    01/04/2020

    1 Media contribution

    Press/Media: Press / Media

Previous 1 2 3 4 5 6 7 Next

ID: 16150437